Mitchell Ho

Mitchell Ho，Chief， Antibody Therapy Section, NIH。Dr. Ho’s laboratory develops new antibody engineering technologies and applies them to advance the development of antibody therapeutics with a focus on glypicans as a new family of tumor antigens. We use 'single domain antibodies' that can reveal novel epitopes unreachable by conventional antibodies and interrupt signaling processes responsible for the development of cancer.